<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724941</url>
  </required_header>
  <id_info>
    <org_study_id>PASS_PD_D440/2</org_study_id>
    <nct_id>NCT04724941</nct_id>
  </id_info>
  <brief_title>Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study</brief_title>
  <acronym>PASS-PD</acronym>
  <official_title>Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PASS-PD study is set out to screen individuals from the general population with an&#xD;
      increased risk for the development of Parkinson's Disease (PD) and to investigate this highly&#xD;
      enriched cohort longitudinally for five year. A special focus is placed on implementation of&#xD;
      ethical standards for early risk disclosure in PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PASS-PP Study is designed to combine the latest developments in clinical and biomarker&#xD;
      research to&#xD;
&#xD;
        1. understand the distribution of risk profiles for PD in the general population,&#xD;
           especially regarding non-motor symptoms&#xD;
&#xD;
        2. identify subjects with a likelihood of developing PD&#xD;
&#xD;
        3. follow individuals with a high likelihood/risk to develop PD in the future (compared to&#xD;
           individuals with low risk and) in a prospective study&#xD;
&#xD;
        4. understand the potential of biological markers to increase prediction of&#xD;
           progression/conversion&#xD;
&#xD;
        5. identify subtypes of PD patients, by providing a detailed clinical phenotyping with a&#xD;
           main focus on non-motor symptoms cluster&#xD;
&#xD;
        6. provide a framework of ethical handling of early risk disclosure in PD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk marker profile</measure>
    <time_frame>Analysis after three years.</time_frame>
    <description>Extend and progression of risk marker profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-motor and motor symptoms</measure>
    <time_frame>Analysis after three years</time_frame>
    <description>Development and progression of non-motor and motor symptoms</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>REM behavior disorder +</arm_group_label>
    <description>Individuals with REM Sleep Behavior Disorder:&#xD;
All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REM behavior disorder -</arm_group_label>
    <description>Individuals without REM Sleep Behavior Disorder with increased risk for PD:&#xD;
All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>REM behavior disorder +</arm_group_label>
    <arm_group_label>REM behavior disorder -</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        General population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 50 and 99&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinical PD at the time of study inclusion&#xD;
&#xD;
          -  Other significant neurologic diseases affecting the central nervous system (e.g.&#xD;
             Multiple sclerosis)&#xD;
&#xD;
          -  other significant diseases e.g. orthopaedic diseases affecting quantitative motor&#xD;
             assessment&#xD;
&#xD;
          -  in case of participation in the lumbal puncture substudy: contraindications for the&#xD;
             performance of lumbal puncture (bleeding tendency, intake of anticoagulants)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Berg, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Neurology, University of Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Schaeffer, Dr.</last_name>
    <phone>004943150023983</phone>
    <email>eva.schaeffer@uksh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department for Neurology, University of Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Eva Sch√§ffer, Dr.</last_name>
      <phone>004943150023983</phone>
      <email>eva.schaeffer@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Eva Schaeffer</investigator_full_name>
    <investigator_title>Dr. Eva Schaeffer, Department for Neurology</investigator_title>
  </responsible_party>
  <keyword>Prodromal</keyword>
  <keyword>Alpha-Synuclein</keyword>
  <keyword>Risk disclosure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After successful analysis and publication of data the clinical data can be shared upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

